Mylan and Biocon have first pegfilgrastim in US

Mylan has received approval from the US Food and Drug Administration (FDA) for the first biosimilar of Amgen’s Neulasta (pegfilgrastim) in the US, with the Fulphila (pegfilgrastim-jmdb) 6mg/0.6ml injectable biosimilar co-developed with Biocon. Expected to be “the first biosimilar pegfilgrastim available in the US”, Fulphila is set to be launched “in the coming weeks”, Mylan anticipates, with a “suite of patient services” to further support patients and caregivers with treatment.

Mylan has received approval from the US Food and Drug Administration (FDA) for the first biosimilar of Amgen’s Neulasta (pegfilgrastim) in the US, with the Fulphila (pegfilgrastim-jmdb) 6mg/0.6ml injectable biosimilar co-developed with Biocon. Expected to be “the first biosimilar pegfilgrastim available in the US”, Fulphila is set to be launched “in the coming weeks”, Mylan anticipates, with a “suite of patient services” to further support patients and caregivers with treatment.

FDA approval was based on review of evidence that included “extensive structural and functional characterisation, animal study data, human pharmacokinetic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By Dean Rudge

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

Endo Offloads Paladin As Shareholders Approve Mallinckrodt Merger

 
• By Dave Wallace

As it prepares to complete its $6.7bn merger with Mallinckrodt, Endo has divested its International Pharmaceuticals business – consisting primarily of Canadian specialty firm Paladin Pharma – to Knight Therapeutics.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.